glp-1 alzheimers 🧐Will GLP-1RA drugs be the future of altzeimers treatement? 🧠There are multiple studies underway assessing the effectiveness of class of medications in prevention and/or delay of dementia 🧠Alzheimer's makes up 60%-80% Repurposing glucagon-like peptide-1 receptor agonists
Description
It is not approved for any of these yet, but the intent is clearly broader metabolic health, not just weight loss
Starting Jan.1, 2026, Pennsylvania will limit GLP1 weightloss drugs under Medicaid threatening access for thousands of lowincome patients.
The Danish drugmaker is making its blockbuster drug Wegovy available through the Hims platform as well as other telehealth companies LifeMD and Ro.
Expert panelists will address everything from how employers are handling covering the new drug to what patients are asking for.
There may also be an increase in strategic partnerships and acquisitions as companies look to bolster their portfolios with proven subq GLP-1 assets
